top of page
The Professional Network for Healthcare Experts
FDA approves OncoSil targeted radiation device for unresectable distal cholangiocarcinoma
The Humanitarian Device Exemption provides adults with unresectable, non-metastatic distal bile duct cancer with a new localised radiation option used alongside systemic therapy, although initial US use will be restricted to five centres participating in a post-approval study.
nuaxia
2 days ago2 min read
British Columbia General Practice Billings Reach C$667,142, 13% Above Manitoba
New physician payment data show general practitioners generated higher median gross billings in British Columbia than in Manitoba.
nuaxia
2 days ago3 min read
British Columbia Family Physician Billings Reach C$704,097, 71% Above Manitoba
New physician payment data show family physicians generated substantially higher median gross billings in British Columbia than in Manitoba.
nuaxia
2 days ago3 min read
British Columbia Urologist Billings Reach C$759,827, 20% Above Manitoba
New physician payment data show urologists generated significantly higher median gross billings in British Columbia than in Manitoba.
nuaxia
2 days ago3 min read
British Columbia ENT Specialist Billings Reach C$771,834, 31% Above Manitoba
New physician payment data show otolaryngologists generated substantially higher median gross billings in British Columbia than in Manitoba.
nuaxia
2 days ago2 min read
Manitoba Gastroenterologist Billings Reach C$856,201, 11% Above British Columbia
New physician payment data show gastroenterologists generated higher median gross billings in Manitoba than in British Columbia.
dan73778
2 days ago2 min read
British Columbia Cardiologist Billings Reach C$945,459, 26% Above Manitoba
New analysis of physician payment data shows cardiologists generated substantially higher median gross billings in British Columbia than in Manitoba.
nuaxia
2 days ago3 min read
Canadian Ophthalmologists Top C$1.18 Million in Gross Billings, Provincial Analysis Finds
New analysis of physician payment data places ophthalmology among Canada's highest-billing specialties, with median gross billings reaching C$1.18 million in British Columbia.
nuaxia
2 days ago3 min read
FDA clears Wandercraft’s Eve self-balancing exoskeleton for personal use in adults with spinal cord injury
The clearance extends Wandercraft’s self-balancing exoskeleton technology beyond supervised rehabilitation, allowing eligible adults with spinal cord injuries to use Eve for hands-free upright mobility and daily activities with a trained companion.
nuaxia
5 days ago2 min read
Sentynl secures option for US alvelestat rights in Phase III-ready AATD lung disease programme
The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.
nuaxia
5 days ago3 min read
Drugmakers curb Swiss reimbursement submissions amid US international drug-pricing concerns
Interpharma says seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for Swiss reimbursement, as companies consider the potential implications of Swiss prices for the US market.
nuaxia
5 days ago3 min read
Health Canada licenses Light AI’s QuickScan Strep A smartphone software for suspected strep throat assessment
The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection.
nuaxia
5 days ago2 min read
PTC Therapeutics wins auction for Sangamo’s ST-920 Fabry gene therapy in deal worth up to $211 million
The acquisition would add a BLA-stage, one-time AAV gene therapy to PTC’s rare disease portfolio, with a rolling US submission expected to complete in the fourth quarter of 2026.
nuaxia
5 days ago3 min read
FDA grants accelerated approval to Zenbexus combination for previously treated multiple myeloma
The approval provides adults who have received at least one prior line of therapy with a new iberdomide-based combination, supported by higher minimal residual disease-negative complete response rates than the comparator regimen in EXCALIBER-RRMM.
nuaxia
5 days ago2 min read
Scotland backs UCB's Zilbrysq while NICE appraisal in England remains unresolved
The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines.
nuaxia
6 days ago2 min read
Philips and Exor extend relationship agreement and raise ownership cap to 22%
The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.
nuaxia
6 days ago2 min read
HanchorBio partners with Taiwan Cancer Moonshot team to advance precision immunotherapy development
The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.
nuaxia
6 days ago2 min read
Mereo grants Sentynl US option for alvelestat in deal worth up to $475 million
The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.
nuaxia
6 days ago3 min read
Alfasigma agrees to acquire Nordic Pharma to expand European specialty care business
The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan.
nuaxia
7 days ago2 min read
Medios agrees to acquire 74% of Caelo to expand European pharmaceutical ingredients business
The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients.
nuaxia
7 days ago2 min read
bottom of page